Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s

Pfizer discontinued its late-stage PCSK9 inhibitor bococizumab after seeing 52-week data showing an unanticipated attenuation of LDL-cholesterol lowering and a higher level of immunogenicity, raising questions about what the impact could be for Amgen’s Repatha and Sanofi/Regeneron’s Praluent.

The wait to see cardiovascular outcomes data on Amgen Inc.’s Repatha (evolocumab) and Sanofi/Regeneron Pharmaceuticals Inc.’s Praluent (alirocumab) just got even more interesting after Pfizer Inc. announced Nov. 1 that it is discontinuing development of its late-stage PCSK9 inhibitor bococizumab due to the clinical profile.

The news – coinciding with the company’s third quarter sales and earnings report – surprised investors because PCSK9 is a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category